Recombinant Human MCSP Protein，GST

The study of MCSP (Melanoma Cell Surface Protein), also known as gp75 or MART-1, has gained significant attention in the field of cancer immunology and targeted therapy, particularly concerning melanoma. MCSP is a transmembrane glycoprotein primarily expressed in melanoma cells and some other melanocyte-related tissues. Its unique expression pattern makes it a promising target for immunotherapeutic approaches, such as monoclonal antibody development and T-cell receptor-based therapies. Research has shown that MCSP plays a crucial role in tumor cell proliferation, survival, and metastatic behavior, thus contributing to melanoma's aggressive characteristics. The protein's capacity to elicit a robust immune response presents opportunities for novel therapeutic strategies aimed at enhancing anti-tumor immunity. Additionally, understanding the molecular mechanisms governing MCSP's function and its interaction with the immune system could pave the way for innovative treatment modalities. Recent advances in recombinant protein technology enable the production and modification of MCSP, allowing for comprehensive studies on its structure-function relationships and potential applications in diagnostic and therapeutic contexts. As the burden of melanoma continues to rise globally, ongoing research into MCSP holds promise for improving patient outcomes through more effective and targeted intervention strategies.